Joel N Maslow
Overview
Explore the profile of Joel N Maslow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
935
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Park S, Lei L, DSouza D, Zipkin R, DiMartini E, Atzampou M, et al.
Nat Commun
. 2023 Aug;
14(1):4896.
PMID: 37580341
Electrospray deposition (ESD) is a promising technique for depositing micro-/nano-scale droplets and particles with high quality and repeatability. It is particularly attractive for surface coating of costly and delicate biomaterials...
2.
Maslow J, Kwon I, Kudchodkar S, Kane D, Tadesse A, Lee H, et al.
Vaccines (Basel)
. 2023 Jun;
11(6).
PMID: 37376404
We highlight the significant progress in developing DNA vaccines during the SARS-CoV-2 pandemic. Specifically, we provide a comprehensive review of the DNA vaccines that have progressed to Phase 2 testing...
3.
Kim W, Roberts C, Song J, Yoon J, Seong H, Hyun H, et al.
Vaccine
. 2023 Jun;
41(29):4206-4211.
PMID: 37296017
Heterologous boost regimens are being increasingly considered against SARS-CoV-2. We report results for the 32 of 45 participants in the Phase 1 CoV2-001 clinical trial (Kim et al., Int J...
4.
Oh S, Jang M, Jung K, Han J, Lee H, Gil A, et al.
Arch Toxicol
. 2023 Jan;
97(4):1177-1189.
PMID: 36683063
pGO-1002, a non-viral DNA vaccine that expresses both spike and ORF3a antigens of SARS-CoV-2, is undergoing phase 1 and phase 2a clinical trials in Korea and the US. A preclinical...
5.
Kim W, Roberts C, Song J, Yoon J, Seong H, Hyun H, et al.
Int J Infect Dis
. 2023 Jan;
128:112-120.
PMID: 36592685
Objectives: The CoV2-001 phase I randomized trial evaluated the safety and immunogenicity of the GLS-5310 bi-cistronic DNA vaccine through 48 weeks of follow-up. Design: A total of 45 vaccine-naïve participants...
6.
Lallow E, Jhumur N, Ahmed I, Kudchodkar S, Roberts C, Jeong M, et al.
Sci Adv
. 2021 Nov;
7(45):eabj0611.
PMID: 34739313
This work reports a suction-based cutaneous delivery method for in vivo DNA transfection. Following intradermal Mantoux injection of plasmid DNA in a rat model, a moderate negative pressure is applied...
7.
Tebas P, Roberts C, Muthumani K, Reuschel E, Kudchodkar S, Zaidi F, et al.
N Engl J Med
. 2021 Sep;
385(12):e35.
PMID: 34525286
Background: Although Zika virus (ZIKV) infection is typically self-limiting, other associated complications such as congenital birth defects and the Guillain-Barré syndrome are well described. There are no approved vaccines against...
8.
Muthumani K, Xu Z, Jeong M, Maslow J, Kalyanaraman V, Srinivasan A
Transl Med Commun
. 2021 Jul;
6(1):13.
PMID: 34230895
The causative agent of the ongoing pandemic in the world is SARS-CoV-2. The research on SARS-CoV-2 has progressed with lightning speed on various fronts, including clinical research and treatment, virology,...
9.
Maslow J, Roberts C
Methods Mol Biol
. 2020 May;
2142:1-8.
PMID: 32367354
From its discovery in Uganda in 1947, Zika virus (ZIKV) was considered a relatively innocuous viral pathogen with sporadic and infrequent occurrence of human infection. It was during an outbreak...
10.
Han J, Sung P, Hong S, Lee H, Koh J, Lee H, et al.
J Hepatol
. 2020 Feb;
73(1):72-83.
PMID: 32088322
Background & Aims: Although direct-acting antiviral (DAA) treatment results in a sustained virologic response (SVR) in most patients with chronic HCV infection, they are at risk of re-infection. Moreover, the...